Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...

The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...

Penang has a higher prevalence of obesity and related health issues compared to the national average, Health Minister Datuk ...

Penangites appear to be slightly heavier than the average Malaysian, according to Health Minister Datuk Seri Dr Dzulkefly Ahmad.

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...